Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 4
2019 1
2020 3
2021 3
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin O, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y. de Joode K, et al. Among authors: mangana j. J Immunother. 2024 Feb 6. doi: 10.1097/CJI.0000000000000506. Online ahead of print. J Immunother. 2024. PMID: 38318726
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, Dulgar O, Eroglu Z, Yeoh HL, Haydon A, Lodde GC, Livingstone E, Khattak A, Kähler K, Hausschild A, McArthur GA, Menzies AM, Long G, Wang W, Carlino MS. Bhave P, et al. Among authors: mangana j. J Immunother Cancer. 2023 Mar;11(3):e006629. doi: 10.1136/jitc-2022-006629. J Immunother Cancer. 2023. PMID: 36889810 Free PMC article.
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Pires da Silva I, et al. Among authors: mangana j. J Immunother Cancer. 2022 Jul;10(7):e004610. doi: 10.1136/jitc-2022-004610. J Immunother Cancer. 2022. PMID: 35798536 Free PMC article.
Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.
Kostner L, Cerminara SE, Pamplona GSP, Maul JT, Dummer R, Ramelyte E, Mangana J, Wagner NB, Cozzio A, Kreiter S, Kogler A, Streit M, Wysocki A, Zippelius A, Läubli H, Navarini AA, Maul LV. Kostner L, et al. Among authors: mangana j. Cancers (Basel). 2022 May 10;14(10):2360. doi: 10.3390/cancers14102360. Cancers (Basel). 2022. PMID: 35625961 Free PMC article.
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Wagner NB, et al. Among authors: mangana j. J Immunother Cancer. 2021 May;9(5):e002350. doi: 10.1136/jitc-2021-002350. J Immunother Cancer. 2021. PMID: 33986126 Free PMC article.
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).
Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, Enk A, Gebhardt C, Gesierich A, Goebeler M, Goerdt S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel JC, Heinzerling L, Kähler KC, Kaume KM, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, Löffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz RKC, Maul LV, Müller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pföhler C, Posch C, Richtig E, Rompel R, Sachse MM, Sauder S, Schadendorf D, Schatton K, Schulze HJ, Schultz E, Schilling B, Schmuth M, Simon JC, Streit M, Terheyden P, Thiem A, Tüting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma). Steeb T, et al. Among authors: mangana j. J Cancer Res Clin Oncol. 2021 Jun;147(6):1763-1771. doi: 10.1007/s00432-020-03450-0. Epub 2020 Nov 21. J Cancer Res Clin Oncol. 2021. PMID: 33219855 Free PMC article.
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. Schilling B, et al. Among authors: mangana j. Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26. Cancer Immunol Immunother. 2019. PMID: 30806748 Free PMC article.
17 results